Amid President Donald Trump’s tweets and statements, no one really knows how his administration will approach drug pricing and regulation. Will the president significantly roll back regulations and force widespread changes at the FDA? Will he take a hard line with drug companies and allow Medicare to negotiate drug prices? And how will this impact innovation in biopharma?
Big players: FDA, Center for Medicare & Medicaid Innovation, Sarepta, Anthem, Humana, UnitedHealthcare
Disruptors: Zipari, Kaleo Pharma, PillPack, Oscar, Clover Health